Genetic invalidation of Lp-PLA$_{2}$ as a therapeutic target: Large-scale study of five functional Lp-PLA$_{2}$-lowering alleles
Accepted version
Peer-reviewed
Repository URI
Repository DOI
Change log
Authors
Abstract
Darapladib, a potent inhibitor of lipoprotein-associated phospholipase A
In 72,657 patients with coronary heart disease and 110,218 controls in 23 epidemiological studies, we genotyped five functional variants: four rare loss-of-function mutations (c.109+2T > C (rs142974898), Arg82His (rs144983904), Val279Phe (rs76863441), Gln287Ter (rs140020965)) and one common modest-impact variant (Val379Ala (rs1051931)) in PLA2G7, the gene encoding Lp-PLA
Lp-PLA
In a large-scale human genetic study, none of a series of Lp-PLA
Description
Keywords
Journal Title
Conference Name
Journal ISSN
2047-4881
Volume Title
Publisher
Publisher DOI
Sponsorship
Medical Research Council (MR/L003120/1)
Medical Research Council (G0800270)
European Research Council (268834)
British Heart Foundation (None)
British Heart Foundation (None)
Medical Research Council (MC_UU_00002/7)
Wellcome Trust (204623/Z/16/Z)
Medical Research Council (G0800270/1)